$2.65
+0.05 (+1.92%)
Open$2.60
Previous Close$2.60
Day High$2.81
Day Low$2.55
52W High$10.19
52W Low$2.20
Volume—
Avg Volume126.2K
Market Cap19.74M
P/E Ratio—
EPS$-7.41
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,457.7% upside
Current
$2.65
$2.65
Target
$41.28
$41.28
$32.58
$41.28 avg
$58.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.64M | 1.62M | 1.37M |
| Net Income | -247,177 | -249,222 | -229,259 |
| Profit Margin | -15.1% | -15.4% | -16.8% |
| EBITDA | -331,691 | -310,875 | -283,649 |
| Free Cash Flow | -127,219 | -197,557 | -123,470 |
| Rev Growth | +20.7% | +12.0% | +3.1% |
| Debt/Equity | 0.09 | 0.11 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |